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Background: Asthma is a common respiratory disease that is characterized by bronchial hyperresponsiveness and
airway obstruction due to chronic airway inflammation. Atopic asthma is a typical IgE-mediated disease in which
the enhanced production of IgE is driven by the activation of Th2 cells, which release a distinct pattern of
cytokines, including interleukin 4 (IL4) and IL3, in response to specific antigen presentation. To evaluate the
methylation status of the whole genomes of bronchial mucosa tissues from subjects who lacked or had
sensitization to Dermatophagoides farina (Df) and Dermatophagoides pteronyssinus (Dp).
Methods: The genome-wide DNA methylation levels in the bronchial mucosa tissues of atopic asthmatics (N = 10),
non-atopic asthmatics (N = 7), and normal controls (N = 7) were examined using microarrays.
Results: In the bronchial mucosa of atopic asthmatics, hypermethylation was detected at 6 loci in 6 genes, while
hypomethylation was detected at 49 loci in 48 genes compared to those of non-atopic asthmatics. Genes that
were assigned the ontologies of multicellular organismal process, response to organic substance, hormone
metabolic process, and growth factor receptor binding were hypomethylated. The methylation levels in the mucosa
of asthmatics and normal controls were similar.
Conclusions: The bronchial mucosa of asthmatics who are atopic to Df or Dp have characteristic methylation
patterns for 52 genes. The genes and pathways identified in the present study may be associated with the
presence of atopy in asthmatics and therefore represent attractive targets for future research.
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Asthma is a common respiratory disease that is charac-
terized by bronchial hyperresponsiveness and airway
obstruction due to chronic airway inflammation [1].
These processes are attributed to the increased expression
of genes for several inflammatory and immune mediators,
including cytokines, chemokines, adhesion molecules,
enzymes, and chemical mediators [2]. The complex traits* Correspondence: hdshin@sogang.ac.kr; mdcspark@hanmail.net
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reproduction in any medium, provided the orthat result from interactions between multiple disease sus-
ceptibility factors and the surrounding environment have
major influences on the onset and severity of asthma [3].
Atopic asthma is a typical IgE-mediated disease in
which the enhanced production of IgE is driven by the
activation of Th2 cells, which release a distinct pattern
of cytokines, including interleukin 4 (IL4) and IL3, in
response to specific antigen presentation [4,5]. Atopy,
which is characterized by the presence of IgE specific for
inhalant allergens or by high-level production of IgE, is
closely associated with asthma development [6]. The
prevalence of asthma has increased throughout the world
over the past three decades [7]. However, wide variations
have been noted among populations of the same races, in-
dicating different exposures to environmental factors [8].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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periods, including the extent of allergens such as obesity,
and exposure to smoking and air pollutants are risk
factors for asthma. Furthermore, asthma is triggered and
exacerbated by outdoor allergens and air pollutants,
including pollens, and microbial and viral pathogens
[9,10,11]. It is noteworthy that many of these indoor and
outdoor inducers/triggers of asthma program the imma-
ture airway during early life, without any effect on the host
DNA, leading to altered asthma risk in later life [12]. Epi-
genetics consists of changes in gene expression due to
mechanisms other than changes to the underlying DNA
sequence [13,14]. These changes may induce phenotypic
change and persist through cell divisions for the remain-
der of the cell's life, possibly lasting for multiple genera-
tions without any change in the intrinsic DNA sequence
of the organism. Epigenetic changes include histone
deacetylation, DNA methylation and non-coding RNAs.
The DNA methylation is the covalent addition of a methyl
group to a cytosine residue in a CpG dinucleotide [15].
Regions of methylated DNA have been correlated with the
tissue-specific expression of several genes and with active
coding regions across the genome [16]. Recently, transi-
tory methylation has been demonstrated for specific gene
regulatory regions [17]. DNA methylation analysis can be
grouped into the mutually exclusive categories of anno-
tated promoters (15%), untranslated regions (UTRs; 7%),
exons (13%), introns (31%), and intergenic segments (34%)
according to each regions [18]. However, the global distri-
bution of DNA methylation in human bronchial mucosa
tissue is unknown, and its role in the development of
asthma has not been reported to date.
The airway inflammation and remodeling that occur in
asthma are characterized by the infiltration of lympho-
cytes and eosinophils into the bronchial mucosa, accom-
panied by structural changes, which include epithelial
desquamation, subepithelial fibrosis, mucus gland hyper-
plasia, modification of the extracellular matrix, and hyper-
trophy/hyperplasia of smooth muscle cells [19,20]. Thus,
bronchial mucosa tissues are suitable for studying the role
of epigenetics in airway responses to environmental
factors, such as indoor allergens. In the present study,
using microarray analyses, we analyzed the genome-wide
DNA methylation profiles of bronchial mucosa tissues
from two groups of asthmatics who lacked or carried spe-
cific IgE to the dust mites Dermatophagoides farina (Df )
and Dermatophagoides pteronyssinus (Dp), and from nor-
mal controls, to reveal the epigenetic differences between
house dust mite-sensitized subjects and naïve subjects.
Methods
Subjects
All samples were obtained after an informed, written con-
sent was obtained from each patient and the protocol wasapproved by the local ethic committee (The ethics
committee's approval number: SCHBC-IRB-2005-02). The
bronchial mucosa tissues from atopic asthmatics for Df
and Dp (N = 10), non-atopic asthmatics (N = 7), and nor-
mal controls (N = 7) were obtained from the Biobank after
the experimental protocol was approved by the Ethics
Committee in the biobank of Soonchunhyang University
Hospital (Schbc-biobank-2011-004). All patients were
diagnosed by physicians and met the definition of asthma
provided in the Global Initiative for Asthma (GINA)
guidelines [1]. All patients had a history of dyspnea and
wheezing during the previous 12 months, plus one of the
following: 1) >15% increase in forced expiratory volume in
1 second (FEV1) or >12% increase plus 200 mL following
inhalation of a short-acting bronchodilator; 2) <10 mg/mL
PC20 methacholine; or 3) >20% increase in FEV1 follow-
ing 2 weeks of treatment with inhaled or systemic cortico-
steroids. The normal subjects, who were recruited from
the spouses of the patients and from the general popula-
tion, answered negatively to a screening questionnaire for
respiratory symptoms [21] and had an FEV1 >75% of the
predicted value, PC20 methacholine >10 mg/ml, and
normal findings on a plain chest X-ray.
Allergy skin prick tests and specific IgE measurements
Allergy skin prick tests were performed using 24 commer-
cial inhalant allergens, which included dust mites (Df and
Dp), fungi, cat fur, dog fur, cockroaches, and grass, tree,
and weed pollens (Bencard Co. Ltd., Brentford, UK). All of
the tests included positive (1 mg/mL histamine) and nega-
tive (diluent) controls. Atopy was defined as having a
wheal reaction equal to or greater than 3 mm in diameter
or equal to or greater than that induced by histamine. IgE
specific for Df and Dp was measured using the CAP
system (Pharmacia Diagnostics, Uppsala, Sweden). The
concentrations were measured in kU/l and expressed
semi-quantitatively as classes 0–6. Sensitization to house
dust mites was confirmed by a positive skin prick test to
house dust mites and elevated allergen-specific IgE level
(greater than score 2). Non-atopy was defined as a nega-
tive skin prick test to all allergens tested and a negative
result for specific IgE (score 0) raised in response to Df
and Dp.
Genomic DNA isolation
All the mucosal biopsies had been taken from the
segmental carinae of the right lower lobe, fixed in 4%
buffered formaldehyde solution, and embedded in para-
ffin blocks. DNA was purified from the tissues using the
QIAamp DNA Blood Mini Kit (Qiagen, Crawley, UK).
Bisulfite conversion
Bisulphite conversion of genomic DNA was done with the
EZ DNA methylation Kit (Zymo Research, Irvine, CA,
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fications for the Illumina Infinium Methylation Assay.
Briefly, one microgram of genomic DNA was first mixed
with 5 μl of M-Dilution Buffer and incubated at 37°C for
15 minutes and then mixed with 100 μl of CT Conversion
Reagent prepared as instructed in the protocol. Mixtures
were incubated in a thermocycler for 16 cycles at 95°C for
30 seconds and 50°C for 60 minutes. Bisulphite-converted
DNA samples were loaded onto 96-column plates pro-
vided in the kit for desulphonation and purification as
instructed in the protocol.
DNA methylation assay and differential DNA methylation
analysis
Bisulphite-converted genomic DNA was analyzed using
Human Methylation27 Beadchip (Illumina, San Diego,
CA, USA). The beadchip contains 27,578 CpG loci cov-
ering more than 14,000 human RefSeq genes at single-
nucleotide resolution. Chip process and data analysis
were performed by using reagents provided in the kit
and by following the manufacturer's manual. Briefly, 4 μl
of bisulphite-converted genomic DNA was denatured in
0.014 N sodium hydroxide, neutralized and amplified
with kit-provided reagents and buffer for 20–24 hours at
37°C. Samples were fragmented. 12 μl of each sample
was loaded onto a 12-sample chip and the chips were
assembled into a hybridization chamber as instructed in
the manual. After incubation at 48°C for 16–20 hours,
chips were washed with wash buffers provided in the kit
and assembled and placed into a fluid flow-through
station for primer-extension reaction and staining with
reagents and buffers provided in the kit. Polymer-coated
chips were image-processed in Illumina's iScan scanner.
Data were extracted using GenomeStudio software.
Methylation values for each CpG locus are expressed as
a beta (β)-value, representing a continuous measurement
from 0 (completely unmethylated) to 1 (completely meth-
ylated). This value is based on following definition and
calculation: β-value = (signal intensity of methylation-
detection probe)/(signal intensity of methylation- detec-
tion probe + signal intensity of non-methylation-detection
probe). The intensity data were normalized using the
background function.
Statistics analysis
To identify differentially methylated CpG sites between
the groups, the difference in mean methylation levels
between the two groups was analyzed using a two-sided
t-test. Assuming a normal distribution of β-value,
DeltaBeta (|Δβ|) was calculated as β for the bronchial
asthma (BA) group minus that for the normal control
(NC) group or atopic asthmatics minus that for the non-
atopic ones. Selection of the differentially methylated
CpG loci between groups was based on (1) a β-valuedifference of >0.10 and (2) a P-value of <0.01. Heatmap
of the differentially methylated CpG sites was done and
viewed by GenomeStudio software. Gene ontology enrich-
ment of DNA methylation profile was performed using
GOTM (http://bioinfo.vanderbilt.edu/gotm/), which is
based on hypergeometric test to show the overrepresented
gene ontology categories (p-value < 0.01) [22]. The p-value
was also calculated according to BINOMDIST function on
the basis of the overrepresentation of gene ontology
categories in hypermethylated and hypomethylated genes
when comparing to all genes on the chip, as a confirm-
ation of the significance of results.
Statistical analyses were performed with SPSS 10.0.
The Mann–Whitney test (two-sample rank-sum test)
was used to analyze differences between two groups. All
data are expressed as median values and interquartile
ranges; significance was defined as P <0.05.
Results
Clinical characteristics of the study subjects
The 17 patients with asthma were classified into two
groups (atopic and non-atopic to Df or Dp) based on the
results of the skin tests and assays for specific IgE to Df
and Dp. The characteristics of the asthmatics and nor-
mal controls are summarized in Table 1. There were no
significant differences in terms of age, sex, smoking ra-
tio, and FEV1 between the atopic and non-atopic pa-
tients. The total IgE concentration and the level of
specific IgE to Df and Dp were significantly higher in the
atopic group than in the non-atopic group (P < 0.03, and
P < 0.001, respectively).
Distribution of DNA methylation levels among the three
groups
DNA methylation levels were measured with Illumina’s
genome-wide methylation assay chip of 27 K CpG sites.
Methylation of the X-chromosome was not considered
in this analysis. Of the 27578 CpG sites, 14363 were lo-
cated within promoter regions, while 13215 loci were in
the gene body. As shown in Figure 1, the methylation
levels in the three groups showed a similar unimodel
distribution, with the highest peak on the x-axis (average
β, 0.1–0.2) and the lowest peak at the right end (average
β, 0.9–1.0). Approximately 50% of the loci had an aver-
age β value <0.2, whereas 0.3% of the loci had an average
β value of 0.9–1.0.
Comparison of DNA methylation patterns of the BA and
NC groups
The methylation levels were similar between the mucosa
of the asthmatics and the normal controls (Figure 2A).
The |Δβ| values for the methylation levels were calculated
as the average β value for the NC group minus that for
the BA group. A volcano plot of the |Δβ| values for each
Table 1 Clinical characteristics of patients with bronchial mucosa tissues for DNA Methylation chip
Clinical profile NC Atopic asthmatics Non atopic asthmatics P-value
NC vs BA in BA
Number 7 10 7
Age, years (range) 50 (22–71) 35 (21–60) 47 (28–78) 0.288 0.133
Sex, male, n(%) 1 (14.3) 4 (40) 1 (14.3) 0.629 0.338
exsmoker/nonsmoker (%) 0 / 7 2 / 8 1 / 6 0.299 0.677
Positive skin test rate (%)* ND 100* 0 - 0.00005
FVC (% predicted) 89.20 ± 10.18 79.50 ± 16.89 90.80 ± 22.26 0.349 0.371
FEV1 (% predicted) 102.00 ± 16.84 78.50 ± 22.54 90.60 ± 20.77 0.119 0.44
FEV1/FVC (% predicted) 85.80 ± 6.18 77.00 ± 15.12 76.20 ± 6.10 0.168 0.513
Body mass index (kg/m2) 23.37 ± 4.08 25.31 ± 1.66 25.92 ± 3.20 0.497 0.37
Total IgE (IU/M) 37.2 663.95 ± 784.99 111.28 ± 99.90 0.267 0.036
Dp. specific IgE (score) ND 4 (2–6) 0 - 0.0005
Df. specific IgE (score) ND 4 (2–6) 0 - 0.0005
Data are presented as mean ± standard deviation or as median (range).
*Positive skin prick test to house dust mites(D. pteronyssinus, or D. farina).
BA:Bronchial asthma; NC:Normal control.
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2A-2. The values ranged from −0.2 to 0.2. Although the
DNA methylation levels were not remarkably different
between the two groups (Figure 2A-1), one methylation
site in a CpG motif in the promoter of LCN6 showed
a significant difference (P < 0.01) in |Δβ| value (0.11)
between the two groups (Table 2).
Comparison of DNA methylation patterns between
asthmatics atopic or non-atopic for Df and Dp
The DNA methylation profiles were similar for the two
groups, with a narrow range of |Δβ| values from −0.2 toFigure 1 Distribution of the DNA methylation levels of BA-atopy, non
methylation level (0–1).0.2. A volcano plot of the |Δβ| values for each locus in
the bronchial mucosa tissues is shown in Figure 2B-2.
To identify the loci that showed atopy-specific changes
in methylation, we applied the following criteria: P ≤ 0.01
and |Δβ| ≥ 0.10. Six loci in six genes in the bronchial
mucosa samples showed significant increases in methy-
lation among the atopic patients, as compared to the
non-atopic patients, whereas 47 loci in 46 genes showed
significant decreases in methylation in these samples
(Table 3). Heat mapping of the β values for the 53 loci
revealed distinct DNA methylation profiles for the bron-
chial mucosa tissues of the atopic and non-atopic groupsatopy and NC in bronchial mucosa. Average beta: DNA
Figure 2 Summary of DNA methylation data. (A-1) Scatter plot of similar methylation levels between BA and NC. (A-2) Volcano plot of the |
Db| values between BA and NC. (B-1) Scatter plot of similar methylation levels between BA-atopy and non atopy. DeltaBeta: difference of DNA
methylation levels. (B-2) Volcano plot of the |Db| values between BA-atopy and non atopy. log(P): log-transformed t-test P-values. (C) Heat map
of 53 methylated CpGs on whole chromosome between the three groups (BA-atopy, BA-non atopy, NC). The DNA methylation profiles were
similar between the three groups.
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within CpG islands, while 29 were outside CpG islands.
In all, 31 loci were identified within promoter regions
(2 kb from the transcriptional start site), while 22 loci
were in the gene body (Table 3).Gene ontology analysis of the differentially methylated
genes in asthmatics atopic or non-atopic for Df and Dp
To examine the biological functions associated with the
genes that had significantly hypomethylated and hyper-
methylated loci, we analyzed the gene ontologic catego-
ries of 52 hypomethylated and hypermethylated genes
using the GOTM program (http://bioinfo.vanderbilt.edu/
gotm/) [22]. The genes present on the Illumina me-
thylation assay chip were used as a reference list. The
genes with hypomethylated loci were assigned to the dis-
tinct gene ontologic categories of multicellular process,
response to organic substance, hormone metabolic process,Table 2 DNA methylation level of CpGs in genes between BA
N TargetID Gene name Chr CpG Position CpG
Coordinate Island
1 cg14611112 LCN6 9 138762801 Promoter FALSEand growth factor receptor binding (Table 4 and Additional
file 1: Table S2).
Discussion
DNA methylation is essential for cell differentiation and
development. Moreover, for many years, DNA methyla-
tion has observed to play a role in regulating gene
expression. Methylation of gene promoter region is corre-
lated with low or no transcription [23]. Recent research
revealed novel insights on the location of DNA hyper-
methylation. Hypermethylation of intra- and intergenic
CpG dinucleotides might contribute to regulating gene ex-
pression by functioning as alternative promoters [24]. For
example, in-depth investigation of the human SHANK3
locus (~60 kb) showed hypermethylation-regulated intra-
genic promoter activity, expressing alternative transcripts
in a tissue- (brain) and cell-type (primary cortical astro-
cyte)–specific manner [24]. In addition, other gene-regu-
lating regions such as enhancers, which are cis-regulatoryand NC
BA vs NC
Beta value of Beta value of DeltaBeta P-value FDR q-value
BA (M ± SD) NC (M ± SD) (NC-BA)
0.46 ± 0.07 0.56 ± 0.04 0.11 0.0008 0.005
Table 3 DNA methylation level of CpGs in genes between BA-atopy and non atopy
BA atopy vs BA non atopy
N TargetID Gene name Chr CpG Coordinate Position CpG Island Beta value of BA atopy
(M ± SD)
Beta value of BA non atopy
(M ± SD)
DeltaBeta
(BA atopy-BA non atopy)
P-value FDR q-value
1 cg15804973 MAP3K5 6 137155349 Promoter TRUE 0.37 ± 0.06 0.26 ± 0.04 0.11 0.0005 -
2 cg18201077 RSAD2 2 6935359 Promoter FALSE 0.29 ± 0.06 0.19 ± 0.03 0.11 0.001 0.005
3 cg24262469 TIPARP 3 157875073 Promoter TRUE 0.42 ± 0.08 0.31 ± 0.03 0.11 0.004 -
4 cg23123362 ICF45 5 157091024 Promoter FALSE 0.39 ± 0.07 0.29 ± 0.03 0.1 0.004 0.007
5 cg06987504 EIF3S6 8 109330128 Promoter TRUE 0.33 ± 0.08 0.22 ± 0.04 0.1 0.007 -
6 cg27398499 TACSTD2 1 58816033 Promoter FALSE 0.41 ± 0.08 0.31 ± 0.05 0.1 0.009 0.009
7 cg23989635 CDH1 16 67328696 Gene body TRUE 0.16 ± 0.03 0.29 ± 0.07 −0.14 0.0001 -
8 cg25368651 C11orf47 11 6475107 Promoter TRUE 0.64 ± 0.06 0.76 ± 0.02 −0.12 0.0002 -
9 cg25427580 B3GALT1 2 168383428 Gene body TRUE 0.63 ± 0.06 0.74 ± 0.03 −0.11 0.0003 -
10 cg18885346 PKHD1 6 52060382 Promoter FALSE 0.57 ± 0.06 0.68 ± 0.04 −0.11 0.0004 0.013
11 cg15309006 LOC63928 16 23673449 Gene body TRUE 0.16 ± 0.05 0.27 ± 0.05 −0.11 0.0005 -
12 cg09272256 AKR1C4 10 5228798 Gene body FALSE 0.56 ± 0.07 0.68 ± 0.03 −0.12 0.0006 0.010
13 cg11532513 LRTM1 3 54937112 Promoter FALSE 0.60 ± 0.05 0.71 ± 0.05 −0.11 0.0007 0.007
14 cg16242770 KRTAP17-1 17 36725473 Gene body FALSE 0.71 ± 0.06 0.82 ± 0.02 −0.1 0.0007 0.006
15 cg00051623 CASP1 11 104411067 Promoter FALSE 0.65 ± 0.07 0.76 ± 0.03 −0.12 0.0008 0.004
16 cg20587168 MGC33407 19 8670172 Gene body TRUE 0.33 ± 0.06 0.46 ± 0.07 −0.13 0.0009 -
17 cg03355526 ZNF454 5 178300830 Gene body TRUE 0.28 ± 0.06 0.39 ± 0.05 −0.11 0.001 -
18 cg24648061 GPR22 7 106901742 Gene body FALSE 0.50 ± 0.07 0.62 ± 0.04 −0.12 0.002 0.007
19 cg11237738 C4orf6 4 5577784 Gene body FALSE 0.54 ± 0.07 0.64 ± 0.02 −0.1 0.002 0.006
20 cg03734874 FLJ42486 14 104142142 Promoter TRUE 0.23 ± 0.06 0.34 ± 0.05 −0.11 0.002 -
21 cg20937139 PDGFC 4 158111996 Promoter TRUE 0.17 ± 0.06 0.28 ± 0.06 −0.11 0.002 -
22 cg26657648 IL1R1 2 102136834 Promoter FALSE 0.64 ± 0.07 0.75 ± 0.03 −0.11 0.002 0.006
23 cg23111544 REG1A 2 79201092 Promoter FALSE 0.57 ± 0.07 0.67 ± 0.03 −0.1 0.002 0.005
24 cg07823755 UGT1A1 2 234333658 Promoter FALSE 0.71 ± 0.07 0.81 ± 0.03 −0.1 0.002 0.005
25 cg13112511 PDE4D 5 58918032 Promoter FALSE 0.59 ± 0.09 0.71 ± 0.03 −0.12 0.002 0.005
26 cg21717724 PSMD5 9 122645027 Gene body TRUE 0.47 ± 0.07 0.59 ± 0.06 −0.12 0.002 -
27 cg08509737 ATG7 3 11315160 Gene body FALSE 0.68 ± 0.07 0.78 ± 0.02 −0.1 0.002 0.004
28 cg05333568 C1orf65 1 221633391 Gene body TRUE 0.29 ± 0.08 0.43 ± 0.08 −0.14 0.003 -
29 cg16398289 WDR49 3 168853983 Promoter FALSE 0.56 ± 0.08 0.66 ± 0.03 −0.11 0.003 0.006
30 cg04527918 UCN 2 27384634 Promoter TRUE 0.42 ± 0.06 0.54 ± 0.08 −0.12 0.003 -



















Table 3 DNA methylation level of CpGs in genes between BA-atopy and non atopy (Continued)
32 cg10430690 KALRN 3 125296275 Gene body TRUE 0.65 ± 0.09 0.77 ± 0.02 −0.11 0.004 -
33 cg15381313 NR1H4 12 99391810 Promoter FALSE 0.50 ± 0.06 0.60 ± 0.07 −0.1 0.004 0.006
34 cg17778867 KRTAP10-8 21 44856424 Gene body FALSE 0.60 ± 0.09 0.71 ± 0.02 −0.12 0.004 0.006
35 cg01216369 SPATA16 3 174341695 Promoter TRUE 0.64 ± 0.08 0.74 ± 0.02 −0.1 0.005 -
36 cg01507173 IL1F5 2 113532686 Gene body FALSE 0.59 ± 0.08 0.69 ± 0.02 −0.1 0.005 0.007
37 cg22152192 CRYM 16 21221918 Promoter FALSE 0.52 ± 0.08 0.63 ± 0.04 −0.1 0.005 0.007
38 cg21053323 SUMO3 21 45062472 Gene body TRUE 0.20 ± 0.07 0.30 ± 0.06 −0.1 0.005 -
39 cg23324787 RAG2 11 36576362 Gene body FALSE 0.57 ± 0.08 0.67 ± 0.03 −0.1 0.005 0.007
40 cg13041032 MMP13 11 102331672 Gene body FALSE 0.64 ± 0.08 0.74 ± 0.03 −0.1 0.005 0.006
41 cg10784090 CLDN18 3 139200348 Promoter TRUE 0.59 ± 0.08 0.70 ± 0.04 −0.1 0.005 -
42 cg04317399 HOXA4 7 27136924 Gene body TRUE 0.26 ± 0.07 0.38 ± 0.09 −0.12 0.006 -
43 cg27202708 C1orf65 1 221633391 Promoter TRUE 0.22 ± 0.07 0.34 ± 0.08 −0.12 0.006 -
44 cg20300655 CATSPER3 5 134331513 Promoter FALSE 0.64 ± 0.08 0.74 ± 0.02 −0.1 0.006 0.007
45 cg10094277 KERA 12 89976262 Gene body FALSE 0.51 ± 0.09 0.62 ± 0.03 −0.11 0.007 0.008
46 cg04117029 UROS 10 127501757 Promoter FALSE 0.60 ± 0.09 0.71 ± 0.03 −0.11 0.007 0.008
47 cg12588299 GPR31 6 167491309 Promoter FALSE 0.50 ± 0.08 0.61 ± 0.05 −0.11 0.007 0.008
48 cg27269921 MN1 22 26527486 Gene body TRUE 0.11 ± 0.03 0.23 ± 0.12 −0.12 0.007 -
49 cg10362591 SLC6A2 16 54248057 Promoter TRUE 0.21 ± 0.06 0.33 ± 0.09 −0.12 0.007 -
50 cg02248486 HOXA5 7 27149812 Gene body TRUE 0.47 ± 0.07 0.57 ± 0.07 −0.1 0.008 -
51 cg04616566 THSD4 15 69807942 Promoter FALSE 0.60 ± 0.09 0.72 ± 0.03 −0.11 0.008 0.009
52 cg19366178 GNB5 15 50270857 Promoter FALSE 0.69 ± 0.09 0.79 ± 0.02 −0.1 0.008 0.008




































UGT1A1, CRYM, AKR1C4 3 0.21 14.37 0.001
Positive regulation
of DNA replication
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Porphyrin
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transport
CRYM, SLC6A2 2 0.11 18.62 0.005
Collagen metabolic
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GNB5, CDH1 2 0.14 14.75 0.008
Hypermethylation Biological
process
Signal transduction MAP3K5, TACSTD2 2 0.13 15.73 0.005
Immune response RSAD2 1 0.05 14.96 0.001





MAP3K5 1 0.04 22.48 0.002
DNA binding TIPARP 1 0.05 18.76 0.004





TACSTD2 1 0.04 14.59 0.009
P-values of enrichment significance below 0.01 were shown.
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of their orientation and distance relative to the TSS, can
be regulated by hypermethylation [25,26]. For example,
hypermethylation-dependent enhancer-like activity, lo-
cated at a CpG island in EGFR2 intron 1, is suggested to
regulate transcription [27]. In the present study, the
methylation levels in the three sample groups had an ave-
rage β value that ranged from 0 to 0.2 for 50% of the loci
on the entire methylome. Continuously expressed genes,
including housekeeping genes, may be included in this
group (Additional file 1: Table S3). The lowest peak,
representing about 0.2% of the loci, was at the right end
(average β, 0.9–1.0). These genes may be densely packed
in nucleosomes. The methylation levels in the three sam-
ple groups showed a similar pattern. However, recent
studies also identified positive associations betweenexpression and methylation level [28-30]. Further gene
expression analysis can be integrated with this DNA
methylation data, and can reach about the exact role of
DNA methylation in controlling gene expression.
Comparing the average β value for each locus in the
bronchial mucosa tissues of the asthmatics atopic to
house dust mites with those of the non-atopic asth-
matics, 47 loci in 46 genes showed significant decreases
in methylation, while 6 loci in 6 genes showed relative
increases in methylation. These data suggest that the
phenotypic differences in atopic sensitization to house
dust mites originate from differences in gene regulation
in the lower airways. Notably, the hypomethylated genes
were linked to multicellular process, hormone metabolic
process, response to organic substance, and growth fac-
tor receptor binding. Changes in the expression levels of
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sensitization to inhaled allergens, such as house dust
mites or pollens.
In the present study, we did not examine the levels of
mRNA expression in the bronchial mucosa of the sub-
jects, since the mucosal biopsy samples were too small
to extract DNA and RNA at the same time. However,
one interesting finding is decrease of the methylation for
mitogen-activated protein kinase 5 (MAP3K5) gene in
non-atopic asthmatics compared to asthmatics atopic
for Dp. The intronic SNP rs9494554, located within
MAP3K5, was associated with atopy in the pooling and
replication samples, and remained significant in the
combined analysis after Bonferroni correction. Other
SNP in MAP3K5 (rs9402839) was nominally significant
for atopy in pooling sample and border significant in the
replication step. MAP3K5 has been found to be associa-
ted with atopy [31]. MAP3K5 encodes a member of the
mitogen-activated protein kinase family that regulates the
activation of the transcription factor activator protein-1
(AP1) in leukotriene D4-stimulated airway smooth muscle
cells and in nitric oxygen-stimulated bronchial epithelial
cells [32,33].
E-cadherin (CDH1) gene polymorphisms are associated
with airway remodelling, inflammation and lung function
decline in individuals with asthma. CDH1 SNPs are asso-
ciated with epithelial E-cadherin expression and suggest
that epithelial adhesion is an important contributor to
airway remodeling and lung function in asthma [34].
In bronchial epithelial cells, Der p 2, which is a major
non-proteolytic allergen of Dp, induced dose-dependent
up-regulation of both mRNA expression and protein
secretion of T cell-directed CC chemokine, granulocyte-
macrophage colony-stimulating factor, IL6, IL8, monocyte
chemotactic protein-1, and macrophage inflammatory
protein-3a via NF-κB and MAPK activation [35,36]. How-
ever, many of the genes identified in the present study
have not been linked with atopy to Dp. Thus, further func-
tional characterization of these genes is needed to clarify
the relationship between the methylation of these genes
and the development of atopy. These mechanisms include
genomic imprinting, histone modification, altered DNA
methylation of regulatory sequences, which may change
asthma risk after conception via environmentally mediated
epigenetic disruption of gene expression [37,38]. Since the
pattern of CpG island methylation is generally cell line-
specific, the sampled airway mucosa should not differ in
cellular composition between the groups. Previous studies
comparing pathologic findings demonstrated that the
histologic appearance of the bronchial mucosa from atopic
asthmatics did not differ from that of non-atopic asth-
matics [39]. Although we did not perform differential
counts of the infiltrating cells and the cells comprising the
bronchial mucosa, the extent of cellular infiltration, asassessed by hematoxylin and eosin staining, was similar in
the two groups (data not shown). However, previous
immunohistochemical studies of bronchial mucosa have
shown different expression patterns of adhesion mole-
cules, cytokines, chemokines, inflammatory mediators,
and their receptors [40,41]. Therefore, we consider that
the difference in methylation patterns is associated with
different stages of cellular differentiation or activation,
rather than the cellular composition of the bronchial
mucosa. The present study confirms the existence of
atopy-associated methylation in bronchial mucosa tissues.
The bronchial mucosa samples from asthmatics with
atopy show characteristic methylation patterns for 52
genes. In addition Limitations of this study are the
relatively small sample size, limited statistical power, and
the lack of gene expression data. Further investigation is
required for a direct correlation analysis between ex-
pression and methylation. In addition, the confounding
effects of contaminated tissues are also possibly influen-
cing methylation levels.Conclusions
Our DNA methylation profiles served as a robust discrim-
inator between asthmatics who are atopic or non-atopic
for the Dp antigen. Functional studies will be valuable in
identifying key genes or pathways that could serve as
biomarkers or therapeutic targets.
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